Latest Biotech News

Guardant Health announced commercial entry into the multi‑cancer detection (MCD) market with its Shield test and reported Q3 earnings that lifted investor sentiment. The company said use of Shield...

Thermo Fisher Scientific agreed to acquire Clario for $8.9 billion in cash (plus an additional earnout), folding the clinical‑trial data and patient‑centric platform into its portfolio. The...

Novo Nordisk made an unsolicited, up-to‑$9 billion two-step offer for obesity biotech Metsera, topping Pfizer’s earlier agreement and triggering a four-business-day window for Pfizer to match or...

The US Food and Drug Administration unveiled draft guidance proposing to eliminate routine Phase III comparative efficacy studies for many biosimilar submissions, aiming to lower development cost...

The FDA placed a formal clinical hold on two late‑stage Intellia trials testing its CRISPR therapy nexiguran ziclumeran after a participant experienced a grade‑4 liver injury with elevated...

4D Molecular Therapeutics sold Asia‑Pacific rights to its retinal gene therapy 4D‑150 to Otsuka Pharmaceutical for $85 million up front plus potential cost‑sharing and up to $336 million in...

Nanobiotix secured a $71 million non‑dilutive loan from HealthCare Royalty to fund operations through early 2028, pledging a portion of future royalties and milestone payments tied to its...

BridgeBio reported that encaleret met primary and key secondary endpoints in a global Phase III study for autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients achieving...

Illumina reported $1.08 billion in Q3 revenues—roughly flat year‑over‑year—and beat adjusted EPS expectations with $1.34, citing strength in clinical sequencing outside China. The company raised...

Eli Lilly reported tirzepatide sales of $10.1 billion in Q3—surpassing prior drug sales leaders and making tirzepatide the world’s top‑selling medicine—then disclosed a $1.2 billion investment to...

10x Genomics launched the next generation of its Chromium Flex assay that scales single‑cell studies by enabling automation‑compatible plate‑based multiplexing—processing up to 384 samples and...

Thermo Fisher Scientific agreed to acquire data‑solutions company Clario for $8.9 billion in cash plus an additional $125 million contingent payment—bringing the deal to about $9.0–$9.4 billion...

Novo Nordisk made a surprise unsolicited bid that values Metsera at roughly $9 billion, prompting Metsera’s board to deem the proposal “superior” to Pfizer’s earlier agreement and giving Pfizer...

The U.S. Food and Drug Administration unveiled draft guidance and public statements aimed at trimming clinical requirements for biosimilars, proposing reduced reliance on comparative efficacy...

The U.S. Food and Drug Administration placed an official clinical hold on two Phase 3 trials of Intellia Therapeutics’ in vivo CRISPR candidate following a serious liver injury in a study...

Eli Lilly reported blockbuster third-quarter sales for tirzepatide products, prompting the company to raise its revenue outlook and plan a $1.2 billion factory in Puerto Rico to scale production...

Thermo Fisher Scientific announced a cash acquisition of Clario, a clinical-trial data solutions company, in a transaction valued at roughly $8.9 billion plus contingent payments. Thermo Fisher is...

10x Genomics launched a next-generation Chromium Flex assay that expands plate-based multiplexing to 384 samples and promises throughput up to hundreds of millions of cells per week. Early-access...

BridgeBio reported positive Phase III results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with a high proportion of patients...

Recursion delivered a whole‑genome microglia phenomap generated from tens of millions of cell images to Roche and Genentech under their AI drug‑discovery pact, triggering a $30 million milestone...